ArticlePLOS global public health2025
"I want to help my body": Acceptability of malaria chemoprevention among children with sickle cell anaemia and their caregivers in Malawi and Uganda.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with sickle cell anaemia (SCA) are at risk of severe illness and death if infected by malaria, and lifelong prophylaxis is recommended to individuals in malaria endemic regions. Although its efficacy is declining due to parasite resistance, the antimalarial drug Sulphadoxine-Pyrimethamine (SP) is still given to patients with SCA in several countries of sub-Saharan Africa. A clinical trial was performed to compare SP with Dihydroartemisinin-Piperaquine (DP) for malaria chemoprevention in children with SCA in Uganda and Malawi. This paper describes a study on acceptability which was nested within the trial. To explore views on malaria chemoprevention and the proposed treatment regimens, 29 focus group discussions were conducted with children above 10 years of age with SCA and caregivers of children with SCA. The discussions were transcribed and translated to English before coding and reflexive thematic analysis. Participants from the DP arm reported a reduced number of sick events and hospital admissions while they were in the trial, and ranked DP above SP in terms of perceived effectiveness. Although concerns were raised about initial side effects, a high pill burden, and the unpleasant smell and taste of tablets, most participants were willing to continue long-term administration of DP due to its observed or experienced health benefits. Despite positive attitudes towards the use of weekly DP, monthly dosing was frequently suggested as a better option as it would lower the pill burden and expand the time interval between treatment courses. To mitigate transport costs and time spent away from school and work, most participants preferred a period of two months or longer between drug refill visits at the hospital. During routine care visits, counselling about the importance of accurate dosing and ongoing adherence should be provided to ensure sustainable and successful use of malaria chemoprevention among children with SCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.